{"id":348562,"date":"2025-08-25T14:42:27","date_gmt":"2025-08-25T14:42:27","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-soleno-therapeutics\/"},"modified":"2025-08-25T14:42:27","modified_gmt":"2025-08-25T14:42:27","slug":"how-to-buy-soleno-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/","title":{"rendered":"How to buy Soleno Therapeutics, Inc. (SLNO) shares &#8211; Investment in Soleno Therapeutics, Inc. (SLNO) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-348562","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Soleno Therapeutics, Inc. (SLNO) Shares - Investment in Soleno Therapeutics, Inc. (SLNO) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Soleno Therapeutics, Inc. (SLNO) Shares - Investment in Soleno Therapeutics, Inc. (SLNO) Stock"},"description":"Learn how to invest in Soleno Therapeutics (SLNO) stock with current price analysis, risk assessment, and step-by-step purchase process for 2025 market opportunities.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to invest in Soleno Therapeutics (SLNO) stock with current price analysis, risk assessment, and step-by-step purchase process for 2025 market opportunities."},"intro":"Thinking about investing in a biotech company that just achieved a historic breakthrough? Soleno Therapeutics (SLNO) represents the exciting intersection of medical innovation and investment potential. With their first FDA-approved therapy hitting the market in 2025, this stock offers both significant upside and classic biotech volatility. Let's explore what makes SLNO compelling right now.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in a biotech company that just achieved a historic breakthrough? Soleno Therapeutics (SLNO) represents the exciting intersection of medical innovation and investment potential. With their first FDA-approved therapy hitting the market in 2025, this stock offers both significant upside and classic biotech volatility. Let's explore what makes SLNO compelling right now."},"body_html":"<h2>\ud83d\udcc8 Current Market Position and Entry Strategy<\/h2> <p>As of August 25, 2025, Soleno Therapeutics (SLNO) trades at <strong>$68.57<\/strong> per share. This price represents an interesting entry point considering the stock reached a 52-week high of $90.32 just last month. The current pullback of approximately 24% from July highs may present a strategic buying opportunity for patient investors.<\/p> <p><strong>Mark Your Calendar: November 5, 2025<\/strong><br> This date is absolutely critical for SLNO investors. The company reports Q3 2025 earnings after market close, and analysts are forecasting something remarkable - the company's <strong>first profitable quarter<\/strong> with consensus EPS of $0.011 (<a href=\"https:\/\/www.moomoo.com\/stock\/SLNO-US\/earnings\">Moomoo Earnings Forecast<\/a>).<\/p> <p>Historical earnings patterns show SLNO has consistently beaten expectations. Their Q2 2025 report on August 6th delivered a stunning surprise - EPS of -$0.09 crushed the expected -$0.53 by $0.44, while revenue of $32.66 million demolished the $3.91 million estimate (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/SLNO\/earnings\/\">MarketBeat Earnings Data<\/a>).<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udd0d Six-Month Price Journey: Rollercoaster with Purpose<\/h2> <p>SLNO's price action over the last six months tells a story of transformation:<\/p> <ul> <li><strong>March 2025<\/strong>: Explosive 46.35% monthly gain as the stock surged from $43.00 to $73.97 on FDA approval excitement (<a href=\"https:\/\/stockscan.io\/stocks\/SLNO\/price-history\">StockScan Price History<\/a>)<\/li> <li><strong>April 2025<\/strong>: Continued momentum with 4.77% gain, though volatility remained high with a $19.55 trading range<\/li> <li><strong>May 2025<\/strong>: Healthy -2.02% pullback as investors took profits after the massive run-up<\/li> <li><strong>June 2025<\/strong>: Strong 14.22% recovery, pushing toward new highs between $72.96-$86.79<\/li> <li><strong>July 2025<\/strong>: Reached the six-month peak at $90.32 with a modest 3.21% gain<\/li> <li><strong>August 2025<\/strong>: Current consolidation around $68-70, representing a 24% retreat from July highs<\/li> <\/ul> <p>This pattern shows classic biotech behavior - explosive moves on regulatory catalysts followed by consolidation phases. The overall trend remains strongly positive with the stock up significantly from March lows.<\/p> <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <ul> <li><strong>2025 Year-End<\/strong>: $85-95 range - Continued commercial execution and potential profitability should drive recovery toward previous highs<\/li> <li><strong>2026 Projection<\/strong>: $100-120 - Full-year revenue generation from VYKAT XR and possible pipeline expansion<\/li> <li><strong>2028 Outlook<\/strong>: $150-180 - Market penetration deepens and potential label expansions drive growth<\/li> <li><strong>2030 Vision<\/strong>: $200+ - Established rare disease franchise with multiple revenue streams<\/li> <\/ul> <p><strong>Verdict<\/strong>: STRONG BUY for long-term investors. The current pullback offers an attractive entry point before November earnings.<\/p> <h2>\u26a0\ufe0f Risk Assessment vs. Positive Signals<\/h2> <p><strong>Risks to Consider:<\/strong><\/p> <ul> <li>Extreme volatility with 150-day implied volatility at 0.4895 (<a href=\"https:\/\/www.alphaquery.com\/stock\/SLNO\/volatility-option-statistics\/150-day\/iv-call\">AlphaQuery Volatility Data<\/a>)<\/li> <li>Short-seller attacks like the recent Scorpion Capital report that caused a 13% drop (<a href=\"https:\/\/www.ainvest.com\/news\/short-selling-biotech-scorpion-capital-bearish-case-soleno-risks-high-stakes-drug-development-2508\/\">AInvest Report<\/a>)<\/li> <li>Heavy dependence on single product VYKAT XR success<\/li> <li>Biotech regulatory uncertainty and clinical trial risks<\/li> <\/ul> <p><strong>Green Lights for 2025:<\/strong><\/p> <ul> <li>FDA approval secured March 26, 2025 - first therapy for Prader-Willi Syndrome hyperphagia<\/li> <li>Strong commercial launch with 646 patient start forms from 295 prescribers in first three months<\/li> <li>Q2 revenue of $32.66 million vastly exceeding $3.91 million expectations<\/li> <li>$293.8 million cash position provides substantial operational runway (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/10\/3113068\/0\/en\/Soleno-Therapeutics-Announces-Preliminary-Financial-and-Operational-Results-for-the-Second-Quarter-Ended-June-30-2025.html\">GlobeNewswire Financials<\/a>)<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Start Small<\/strong>: Begin with a position size you can hold through volatility - biotech requires strong stomachs<\/li> <li><strong>Dollar-Cost Average<\/strong>: Consider building your position gradually rather than going all-in at once<\/li> <li><strong>Set Alert for November 5<\/strong>: Mark your calendar for earnings - this could be a major inflection point<\/li> <li><strong>Diversify Appropriately<\/strong>: Keep biotech allocations reasonable within your overall portfolio<\/li> <\/ol> <p>Humorous take: \"Trading SLNO is like dating a brilliant scientist - incredibly exciting potential, but prepare for some dramatic mood swings and complicated explanations!\"<\/p> <h2>\u2705 How to Buy Soleno Therapeutics, Inc. (SLNO) Shares - Step by Step<\/h2> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>Step<\/th> <th>Action<\/th> <th>Why It Matters<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Choose Your Platform<\/td> <td>Select a broker that offers NASDAQ access and reasonable commission rates<\/td> <\/tr> <tr> <td>2<\/td> <td>Fund Your Account<\/td> <td>Transfer funds - consider starting with an amount you're comfortable potentially losing<\/td> <\/tr> <tr> <td>3<\/td> <td>Search \"SLNO\"<\/td> <td>Use the exact ticker symbol, not just the company name<\/td> <\/tr> <tr> <td>4<\/td> <td>Set Order Type<\/td> <td>Use limit orders to control your entry price in volatile stocks<\/td> <\/tr> <tr> <td>5<\/td> <td>Review and Execute<\/td> <td>Double-check order details before confirming purchase<\/td> <\/tr> <tr> <td>6<\/td> <td>Monitor Position<\/td> <td>Set price alerts for both upside targets and stop-loss levels<\/td> <\/tr> <tr> <td>7<\/td> <td>Track Earnings Calendar<\/td> <td>Mark November 5th and future reporting dates<\/td> <\/tr> <tr> <td>8<\/td> <td>Stay Informed<\/td> <td>Follow company news and analyst updates regularly<\/td> <\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2> <p>For those beginning their investment journey, Pocket Option offers several advantages for testing strategies with Soleno Therapeutics stock:<\/p> <p><strong>Minimum deposit of just $5<\/strong> allows you to experiment with small positions while learning biotech investing dynamics. The platform's <strong>1-minute KYC process<\/strong> using any single document means you can start trading almost immediately after account creation. With <strong>over 100 withdrawal methods<\/strong> including various cryptocurrencies, e-wallets, and traditional banking options, you maintain flexibility with your funds.<\/p> <p>The platform's user-friendly interface makes monitoring volatile stocks like SLNO more manageable, while the low entry barrier means you can gain practical experience without committing significant capital during your learning phase.<\/p> <h2>\ud83c\udf0d Soleno Therapeutics in 2025: Rare Disease Pioneer<\/h2> <p>Soleno Therapeutics has achieved something remarkable in 2025 - transitioning from clinical-stage development to commercial success with VYKAT XR, the first FDA-approved therapy specifically for Prader-Willi Syndrome hyperphagia. The company's focus on rare genetic disorders positions it in a specialty niche with limited competition and significant pricing power.<\/p> <p>Headquartered in Redwood City, California, Soleno employs 92 dedicated professionals led by CEO Dr. Anish Bhatnagar. The company's transformation this year represents a case study in successful biotech development - from research through approval to commercial execution.<\/p> <p><strong>Interesting Fact for 2025<\/strong>: In their first quarter of commercial sales (Q2 2025), Soleno generated $32.66 million in revenue from VYKAT XR, which was approximately 735% higher than analyst expectations of $3.91 million. This staggering beat demonstrates both the unmet medical need in Prader-Willi Syndrome and the company's effective commercial launch strategy.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Current Market Position and Entry Strategy<\/h2>\n<p>As of August 25, 2025, Soleno Therapeutics (SLNO) trades at <strong>$68.57<\/strong> per share. This price represents an interesting entry point considering the stock reached a 52-week high of $90.32 just last month. The current pullback of approximately 24% from July highs may present a strategic buying opportunity for patient investors.<\/p>\n<p><strong>Mark Your Calendar: November 5, 2025<\/strong><br \/> This date is absolutely critical for SLNO investors. The company reports Q3 2025 earnings after market close, and analysts are forecasting something remarkable &#8211; the company&#8217;s <strong>first profitable quarter<\/strong> with consensus EPS of $0.011 (<a href=\"https:\/\/www.moomoo.com\/stock\/SLNO-US\/earnings\">Moomoo Earnings Forecast<\/a>).<\/p>\n<p>Historical earnings patterns show SLNO has consistently beaten expectations. Their Q2 2025 report on August 6th delivered a stunning surprise &#8211; EPS of -$0.09 crushed the expected -$0.53 by $0.44, while revenue of $32.66 million demolished the $3.91 million estimate (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/SLNO\/earnings\/\">MarketBeat Earnings Data<\/a>).<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd0d Six-Month Price Journey: Rollercoaster with Purpose<\/h2>\n<p>SLNO&#8217;s price action over the last six months tells a story of transformation:<\/p>\n<ul>\n<li><strong>March 2025<\/strong>: Explosive 46.35% monthly gain as the stock surged from $43.00 to $73.97 on FDA approval excitement (<a href=\"https:\/\/stockscan.io\/stocks\/SLNO\/price-history\">StockScan Price History<\/a>)<\/li>\n<li><strong>April 2025<\/strong>: Continued momentum with 4.77% gain, though volatility remained high with a $19.55 trading range<\/li>\n<li><strong>May 2025<\/strong>: Healthy -2.02% pullback as investors took profits after the massive run-up<\/li>\n<li><strong>June 2025<\/strong>: Strong 14.22% recovery, pushing toward new highs between $72.96-$86.79<\/li>\n<li><strong>July 2025<\/strong>: Reached the six-month peak at $90.32 with a modest 3.21% gain<\/li>\n<li><strong>August 2025<\/strong>: Current consolidation around $68-70, representing a 24% retreat from July highs<\/li>\n<\/ul>\n<p>This pattern shows classic biotech behavior &#8211; explosive moves on regulatory catalysts followed by consolidation phases. The overall trend remains strongly positive with the stock up significantly from March lows.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<ul>\n<li><strong>2025 Year-End<\/strong>: $85-95 range &#8211; Continued commercial execution and potential profitability should drive recovery toward previous highs<\/li>\n<li><strong>2026 Projection<\/strong>: $100-120 &#8211; Full-year revenue generation from VYKAT XR and possible pipeline expansion<\/li>\n<li><strong>2028 Outlook<\/strong>: $150-180 &#8211; Market penetration deepens and potential label expansions drive growth<\/li>\n<li><strong>2030 Vision<\/strong>: $200+ &#8211; Established rare disease franchise with multiple revenue streams<\/li>\n<\/ul>\n<p><strong>Verdict<\/strong>: STRONG BUY for long-term investors. The current pullback offers an attractive entry point before November earnings.<\/p>\n<h2>\u26a0\ufe0f Risk Assessment vs. Positive Signals<\/h2>\n<p><strong>Risks to Consider:<\/strong><\/p>\n<ul>\n<li>Extreme volatility with 150-day implied volatility at 0.4895 (<a href=\"https:\/\/www.alphaquery.com\/stock\/SLNO\/volatility-option-statistics\/150-day\/iv-call\">AlphaQuery Volatility Data<\/a>)<\/li>\n<li>Short-seller attacks like the recent Scorpion Capital report that caused a 13% drop (<a href=\"https:\/\/www.ainvest.com\/news\/short-selling-biotech-scorpion-capital-bearish-case-soleno-risks-high-stakes-drug-development-2508\/\">AInvest Report<\/a>)<\/li>\n<li>Heavy dependence on single product VYKAT XR success<\/li>\n<li>Biotech regulatory uncertainty and clinical trial risks<\/li>\n<\/ul>\n<p><strong>Green Lights for 2025:<\/strong><\/p>\n<ul>\n<li>FDA approval secured March 26, 2025 &#8211; first therapy for Prader-Willi Syndrome hyperphagia<\/li>\n<li>Strong commercial launch with 646 patient start forms from 295 prescribers in first three months<\/li>\n<li>Q2 revenue of $32.66 million vastly exceeding $3.91 million expectations<\/li>\n<li>$293.8 million cash position provides substantial operational runway (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/10\/3113068\/0\/en\/Soleno-Therapeutics-Announces-Preliminary-Financial-and-Operational-Results-for-the-Second-Quarter-Ended-June-30-2025.html\">GlobeNewswire Financials<\/a>)<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Start Small<\/strong>: Begin with a position size you can hold through volatility &#8211; biotech requires strong stomachs<\/li>\n<li><strong>Dollar-Cost Average<\/strong>: Consider building your position gradually rather than going all-in at once<\/li>\n<li><strong>Set Alert for November 5<\/strong>: Mark your calendar for earnings &#8211; this could be a major inflection point<\/li>\n<li><strong>Diversify Appropriately<\/strong>: Keep biotech allocations reasonable within your overall portfolio<\/li>\n<\/ol>\n<p>Humorous take: &#8220;Trading SLNO is like dating a brilliant scientist &#8211; incredibly exciting potential, but prepare for some dramatic mood swings and complicated explanations!&#8221;<\/p>\n<h2>\u2705 How to Buy Soleno Therapeutics, Inc. (SLNO) Shares &#8211; Step by Step<\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose Your Platform<\/td>\n<td>Select a broker that offers NASDAQ access and reasonable commission rates<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Fund Your Account<\/td>\n<td>Transfer funds &#8211; consider starting with an amount you&#8217;re comfortable potentially losing<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Search &#8220;SLNO&#8221;<\/td>\n<td>Use the exact ticker symbol, not just the company name<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Set Order Type<\/td>\n<td>Use limit orders to control your entry price in volatile stocks<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Review and Execute<\/td>\n<td>Double-check order details before confirming purchase<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Monitor Position<\/td>\n<td>Set price alerts for both upside targets and stop-loss levels<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Track Earnings Calendar<\/td>\n<td>Mark November 5th and future reporting dates<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Stay Informed<\/td>\n<td>Follow company news and analyst updates regularly<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2>\n<p>For those beginning their investment journey, Pocket Option offers several advantages for testing strategies with Soleno Therapeutics stock:<\/p>\n<p><strong>Minimum deposit of just $5<\/strong> allows you to experiment with small positions while learning biotech investing dynamics. The platform&#8217;s <strong>1-minute KYC process<\/strong> using any single document means you can start trading almost immediately after account creation. With <strong>over 100 withdrawal methods<\/strong> including various cryptocurrencies, e-wallets, and traditional banking options, you maintain flexibility with your funds.<\/p>\n<p>The platform&#8217;s user-friendly interface makes monitoring volatile stocks like SLNO more manageable, while the low entry barrier means you can gain practical experience without committing significant capital during your learning phase.<\/p>\n<h2>\ud83c\udf0d Soleno Therapeutics in 2025: Rare Disease Pioneer<\/h2>\n<p>Soleno Therapeutics has achieved something remarkable in 2025 &#8211; transitioning from clinical-stage development to commercial success with VYKAT XR, the first FDA-approved therapy specifically for Prader-Willi Syndrome hyperphagia. The company&#8217;s focus on rare genetic disorders positions it in a specialty niche with limited competition and significant pricing power.<\/p>\n<p>Headquartered in Redwood City, California, Soleno employs 92 dedicated professionals led by CEO Dr. Anish Bhatnagar. The company&#8217;s transformation this year represents a case study in successful biotech development &#8211; from research through approval to commercial execution.<\/p>\n<p><strong>Interesting Fact for 2025<\/strong>: In their first quarter of commercial sales (Q2 2025), Soleno generated $32.66 million in revenue from VYKAT XR, which was approximately 735% higher than analyst expectations of $3.91 million. This staggering beat demonstrates both the unmet medical need in Prader-Willi Syndrome and the company&#8217;s effective commercial launch strategy.<\/p>\n"},"faq":[{"question":"What is Soleno Therapeutics' main business?","answer":"Soleno is a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, with their flagship product VYKAT XR being the first FDA-approved treatment for Prader-Willi Syndrome hyperphagia."},{"question":"Why is SLNO stock so volatile?","answer":"As a clinical-stage biotech company transitioning to commercial operations, SLNO experiences high volatility due to regulatory developments, clinical trial results, earnings surprises, and the inherent risks of single-product dependency."},{"question":"When is the next important date for SLNO investors?","answer":"November 5, 2025, when the company reports Q3 earnings. Analysts are forecasting the company's first profitable quarter, which could be a significant milestone."},{"question":"What makes SLNO different from other biotech stocks?","answer":"SLNO has already achieved FDA approval and commercial launch success in 2025, putting it ahead of many clinical-stage biotechs that remain years away from revenue generation."},{"question":"Is now a good time to invest in SLNO?","answer":"The current pullback from July highs around $68 presents a potential entry point, especially with strong Q2 results and optimistic Q3 forecasts. However, biotech investments always carry higher risk and require careful position sizing."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"What is Soleno Therapeutics' main business?","answer":"Soleno is a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, with their flagship product VYKAT XR being the first FDA-approved treatment for Prader-Willi Syndrome hyperphagia."},{"question":"Why is SLNO stock so volatile?","answer":"As a clinical-stage biotech company transitioning to commercial operations, SLNO experiences high volatility due to regulatory developments, clinical trial results, earnings surprises, and the inherent risks of single-product dependency."},{"question":"When is the next important date for SLNO investors?","answer":"November 5, 2025, when the company reports Q3 earnings. Analysts are forecasting the company's first profitable quarter, which could be a significant milestone."},{"question":"What makes SLNO different from other biotech stocks?","answer":"SLNO has already achieved FDA approval and commercial launch success in 2025, putting it ahead of many clinical-stage biotechs that remain years away from revenue generation."},{"question":"Is now a good time to invest in SLNO?","answer":"The current pullback from July highs around $68 presents a potential entry point, especially with strong Q2 results and optimistic Q3 forecasts. However, biotech investments always carry higher risk and require careful position sizing."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Soleno Therapeutics, Inc. (SLNO) shares - Investment in Soleno Therapeutics, Inc. (SLNO) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Soleno Therapeutics, Inc. (SLNO) shares - Investment in Soleno Therapeutics, Inc. (SLNO) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T14:42:27+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Soleno Therapeutics, Inc. (SLNO) shares &#8211; Investment in Soleno Therapeutics, Inc. (SLNO) stock\",\"datePublished\":\"2025-08-25T14:42:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/\",\"name\":\"How to buy Soleno Therapeutics, Inc. (SLNO) shares - Investment in Soleno Therapeutics, Inc. (SLNO) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"datePublished\":\"2025-08-25T14:42:27+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Soleno Therapeutics, Inc. (SLNO) shares &#8211; Investment in Soleno Therapeutics, Inc. (SLNO) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Soleno Therapeutics, Inc. (SLNO) shares - Investment in Soleno Therapeutics, Inc. (SLNO) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Soleno Therapeutics, Inc. (SLNO) shares - Investment in Soleno Therapeutics, Inc. (SLNO) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T14:42:27+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Soleno Therapeutics, Inc. (SLNO) shares &#8211; Investment in Soleno Therapeutics, Inc. (SLNO) stock","datePublished":"2025-08-25T14:42:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/","name":"How to buy Soleno Therapeutics, Inc. (SLNO) shares - Investment in Soleno Therapeutics, Inc. (SLNO) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","datePublished":"2025-08-25T14:42:27+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-soleno-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Soleno Therapeutics, Inc. (SLNO) shares &#8211; Investment in Soleno Therapeutics, Inc. (SLNO) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":348748,"slug":"how-to-buy-soleno-therapeutics","post_title":"Comment acheter des actions de Soleno Therapeutics, Inc. (SLNO) - Investissement dans les actions de Soleno Therapeutics, Inc. (SLNO)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-soleno-therapeutics\/"},"it_IT":{"locale":"it_IT","id":348751,"slug":"how-to-buy-soleno-therapeutics","post_title":"Come acquistare azioni Soleno Therapeutics, Inc. (SLNO) - Investire in azioni Soleno Therapeutics, Inc. (SLNO)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-soleno-therapeutics\/"},"pl_PL":{"locale":"pl_PL","id":348754,"slug":"how-to-buy-soleno-therapeutics","post_title":"Jak kupi\u0107 akcje Soleno Therapeutics, Inc. (SLNO) - Inwestycja w akcje Soleno Therapeutics, Inc. (SLNO)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-soleno-therapeutics\/"},"es_ES":{"locale":"es_ES","id":348750,"slug":"how-to-buy-soleno-therapeutics","post_title":"C\u00f3mo comprar acciones de Soleno Therapeutics, Inc. (SLNO) - Inversi\u00f3n en acciones de Soleno Therapeutics, Inc. (SLNO)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-soleno-therapeutics\/"},"th_TH":{"locale":"th_TH","id":348753,"slug":"how-to-buy-soleno-therapeutics","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Soleno Therapeutics, Inc. (SLNO) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Soleno Therapeutics, Inc. (SLNO)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-soleno-therapeutics\/"},"tr_TR":{"locale":"tr_TR","id":348749,"slug":"how-to-buy-soleno-therapeutics","post_title":"Soleno Therapeutics, Inc. (SLNO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Soleno Therapeutics, Inc. (SLNO) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-soleno-therapeutics\/"},"vt_VT":{"locale":"vt_VT","id":348747,"slug":"how-to-buy-soleno-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Soleno Therapeutics, Inc. (SLNO) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Soleno Therapeutics, Inc. (SLNO)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-soleno-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":348752,"slug":"how-to-buy-soleno-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Soleno Therapeutics, Inc. (SLNO) - Investimento em a\u00e7\u00f5es da Soleno Therapeutics, Inc. (SLNO)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-soleno-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/348562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=348562"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/348562\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334072"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=348562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=348562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=348562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}